Skip to content

Sevoflurane

General Anesthetic — NERVOUS SYSTEM

Also known as: sevoflo, sevofluran, sevofrane, sevorane

OfpFDA approvedATC N01AB08

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Sevoflurane is an ofp drug in the General Anesthetic class catalogued in DrugCentral. It was first approved by the FDA in 1995. DrugCentral lists 7 molecular targets, including GLRA1, KCNK2 and KCNK3. Recorded indications include General anesthesia.

  • Approval status: ofp (first approved 1995 by the FDA).
  • Drug class: General Anesthetic.
  • Molecular targets: GLRA1, KCNK2, KCNK3 and KCNK9 (7 listed in DrugCentral).
  • Indications: General anesthesia.
  • ATC code: N01AB08 (Halogenated hydrocarbons).
  • Molecular formula: C4H3F7O; molecular weight 200.06 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

  • General anesthesia

Contraindications (10)

  • Benign intracranial hypertension
  • Disease of liver
  • Duchenne muscular dystrophy
  • Glycosuria
  • Hyperkalemia
  • Kidney disease
  • Low blood pressure
  • Malignant hyperthermia
  • Proteinuria
  • Seizure disorder

Mechanism & targets

Established pharmacologic classGeneral Anesthetic

Molecular targets (7)

TargetGeneActionActivity
Glycine receptor subunit alpha-1GLRA1other—
Potassium channel subfamily K member 2KCNK2opener—
Potassium channel subfamily K member 3KCNK3opener—
Potassium channel subfamily K member 9KCNK9opener—
Potassium channel subfamily K member 10KCNK10opener—
Potassium channel subfamily K member 18KCNK18opener—
GABA-A receptor; anion channelGABRP|GABRD|GABRA1|GABRB1|GABRG2|GABRB3|GABRA5|GABRA3|GABRA2|GABRB2|GABRA4|GABRE|GABRA6|GABRG1|GABRG3|GABRQpositive allosteric modulator—

Regulatory approvals (1)

DateAgencyMarketed asApplicantOrphan
1995-06-07FDA—ABBVIE

ATC classification

ATC codeTherapeutic hierarchy
N01AB08NERVOUS SYSTEM › ANESTHETICS › ANESTHETICS, GENERAL › Halogenated hydrocarbons

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

  • EMA label
  • FDA label: CACNA1S, RYR1 · Actionable PGx
  • HCSC label: CACNA1S, RYR1 · Actionable PGx

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Anaesthetic complication neurological1919.9
Hyperthermia malignant1466.0
Anaesthetic complication977.6
Delayed recovery from anaesthesia932.7
Unwanted awareness during anaesthesia684.7
Anaphylactic shock603.3
Cardiac arrest593.4
Hypotension592.8
Bradycardia517.4
Serotonin syndrome505.5
Post procedural complication473.1
Bronchospasm403.2

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Sevoflurane is on its molecule page.

Molecular formulaC4H3F7O
Molecular weight200.06 g/mol
CAS number28523-86-6
InChIKeyDFEYYRMXOJXZRJ-UHFFFAOYSA-N
PubChem CID5206
FCOC(C(F)(F)F)C(F)(F)F

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Sevoflurane used for?

DrugCentral lists the following indications for Sevoflurane: General anesthesia.

How does Sevoflurane work?

Its molecular targets in DrugCentral include GLRA1, KCNK2 (opener), KCNK3 (opener) and KCNK9 (opener).

When was Sevoflurane first approved?

Sevoflurane was first approved by the FDA in 1995.

What drug class does Sevoflurane belong to?

Sevoflurane is in the General Anesthetic class.

What is the chemical formula of Sevoflurane?

Sevoflurane has the molecular formula C4H3F7O and a molecular weight of 200.06 g/mol.

Browse: all drugs starting with S · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusOFP
First approval1995-06-07
AgencyFDA
Targets7
Indications1
FormulaC4H3F7O
DrugCentral ID2439
Interactive profile